DSM Biologics and Crucell enter antibody production deal with Biotecnol

Published: 5-Jan-2007


DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology partner Crucell have signed a license agreement with Portuguese biotechnology company, Biotecnol SA, and its US-based subsidiary.

The agreement allows Biotecnol to use the PER.C6 human cell line for preclinical and phase 1 clinical development of its proprietary antibody products, which are composed of Tribodies and Compact Antibodies.

"We believe that by adopting the PER.C6 production platform, we will be able to develop our products in a robust, cost efficient and most importantly, in a timely way, due to its characteristics and ease of manipulation", said Pedro de Noronha Pissarra, ceo of Biotecnol.

Under the agreement, Biotecnol will make license payments and annual maintenance fees in exchange for certain rights. Further financial details were not disclosed. Biotecnol applies its antibody technologies, product development and manufacturing experience to generate, support and potentially license out human antibody products.

You may also like